OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Hematology & Oncology is 78. The table below lists those papers that are above that threshold based on CrossRef citation counts. The publications cover those that have been published in the past four years, i.e., from 2019-03-01 to 2023-03-01.)

Article	Citations
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications	564
Ferroptosis, a new form of cell death: opportunities and challenges in cancer	529
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity	430
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy	369
Targeting mTOR for cancer therapy	365
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics	345
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy	281
The interplay between m6A RNA methylation and noncoding RNA in cancer	251
RETRACTED ARTICLE: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance a	233
The role of stromal cancer-associated fibroblasts in pancreatic cancer	223
Nanotechnology in cancer diagnosis: progress, challenges and opportunities	190
Tumor neoantigens: from basic research to clinical applications	188
CircRNAs in cancer metabolism: a review	184
LSD1/KDM1A inhibitors in clinical trials: advances and prospects	181
Emerging therapies for small cell lung cancer	181
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy	167
Cancer-associated adipocytes: key players in breast cancer progression	164
Technologies for circulating tumor cell separation from whole blood	162
Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017	162
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy	149
Noncoding RNAs in cancer therapy resistance and targeted drug development	143
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy	134
Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting	131
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy	128
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer	117
miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization	117
Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer	111
The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy	111
lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer	109
Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression	108
Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia	104
LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	104
CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis	97
Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment	93
Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer	92
Emerging organoid models: leaping forward in cancer research	92
Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study	90
Target selection for CAR-T therapy	89
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma	87
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies	87
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies	86
DLL3: an emerging target in small cell lung cancer	83
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients	82
Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment	81
Recent drug approvals for acute myeloid leukemia	80
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment	80
Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation	78